April 10, 2017 / 12:26 PM / 7 months ago

OncoMed's pancreatic cancer drug fails mid-stage study

April 10 (Reuters) - OncoMed Pharmaceuticals Inc said on Monday its experimental drug, in combination with Celgene Corp’s Abraxane and chemotherapy, failed a mid-stage study as an initial therapy for advanced pancreatic cancer.

The trial was testing OncoMed’s demcizumab, Abraxane and chemotherapy versus a combination of Abraxane, chemotherapy and a placebo.

The main goal was to slow disease progression.

Based on the lack of benefit over standard-of-care, which performed remarkably well, the company will discontinue the trial, OncoMed CEO Paul Hastings said. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below